Dr. Reddys Lab Latest News

  1. The company’s Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients
    Date:04-12-2019
  2. The company’s Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients
    Date:04-12-2019
  3. Pursuant to Regulation 23(9) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Reddys Laboratories has informed that it has enclosed the applicable disclosure on rela...

    Date:28-11-2019
  4. The company has received approval for Doxercalciferol injection from USFDA
    Date:25-11-2019
  5. Dr. Reddy’s Laboratories has informed that the company enclosed a press release on ‘Dr. Reddy’s Laboratories announces launch of Doxercalciferol Injection in the US Market’.

    The above information is a part of ...

    Date:22-11-2019
  6. The company has received approval for Doxercalciferol injection from USFDA
    Date:22-11-2019
  7. The company which won the tender to market Olanzapine drug in China, is expected to launch it beginning next year
    Date:22-11-2019
  8. It’s a first-of-its-kind under company's nutrition portfolio and clinically proven to help manage blood glucose levels among Indian patients
    Date:14-11-2019
  9. The award acknowledges the company’s proactive and methodical approach in addressing the global Sartan APIs concern
    Date:13-11-2019
  10. Total consolidated income of the company increased by 23.34% at Rs 4,866.80 crore for Q2FY20
    Date:01-11-2019
Return to Top
Puchho Befikar